| Literature DB >> 35860561 |
Zihong Zhu1,2, Guanzhong Gong2, Lizhen Wang2, Ya Su2, Jie Lu2, Yong Yin1,2.
Abstract
Objective: The present study aimed to evaluate the feasibility of sub-volume segmentation for radiotherapy planning of adult non-enhancing low-grade gliomas (NE-LGGs) guided by three-dimensional arterial spin labeling (3D-ASL). The differences in high- and low-perfusion areas of NE-LGGs were analyzed using multi-sequence magnetic resonance imaging (MRI) radiomics.Entities:
Keywords: low-grade gliomas; non-enhancing; radiomics; sub-volume segmentation; three-dimensional arterial spin labeling
Year: 2022 PMID: 35860561 PMCID: PMC9291222 DOI: 10.3389/fonc.2022.914507
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 5.738
Clinical characteristics of all patients.
| Characteristics | Number of patients (%) |
|---|---|
| Age (mean ± SD, year; range) | 49 ± 14 (31–74) |
| Gender | |
| Female | 5 (33%) |
| Male | 10 (67%) |
| Tumor location | |
| Unilateral | 7 (47%) |
| Midlinea (H3 K27-altered status) | 5 (33%) |
| Altered | 0 (0%) |
| Non-altered | 5 (33%) |
| Bilateral (widely diffuse distribution) | 3 (20%) |
| Type of histopathology | |
| Astrocytoma | 15 (100%) |
| WHO classification | |
| Grade 2 | 15 (100%) |
| IDH mutation status | |
| Mutant | 1 (7%) |
| Wild type | 10 (67%) |
| NOS | 4 (26%) |
| Median follow-up timeb, Median (range) | 12 months (1–29 months) |
aMidline location includes brainstem, thalamus, cerebellum. bThe follow-up method was done according to RANO criteria (20). SD, standard deviation. NOS, not otherwise specified. IDH, isocitrate dehydrogenase.
The common parameters of MRI sequences.
| Parameters | T1WI | T2 Propeller | T2 FLAIR | CE-T1WI | 3D-ASL |
|---|---|---|---|---|---|
| TR (ms) | 8.5 | 13,500 | 11,000 | 8.5 | 5,160 |
| TE (ms) | 3.2 | 114 | 120 | 3.2 | 11.5 |
| FOV (cm) | 25.6 × 25.6 | 26 × 26 | 26 × 26 | 25.6 × 25.6 | 25.6 × 25.6 |
| Matrix | 256 × 256 | 416 × 416 | 320 × 320 | 256 × 256 | 512 × 512 |
| Flip angle (°) | 12 | 120 | 160 | 12 | 110 |
T1WI, T1-weighted imaging; T2 FLAIR, T2 fluid-attenuated inversion recovery; 3D-ASL, three-dimensional arterial spin labeling; CE-T1WI, contrast-enhanced T1WI; TR, repetition time; TE, echo time; FOV, field of view.
Figure 1Flow chart of this study. (A, D), fusion images of T2 Flair and 3D-ASL; (B) T2 Flair image; (C, E), local magnification of (A, D), respectively.
The CBF values of sub-volume before radiotherapy (ml/100 g/min).
| High-perfusion area | Edema area | Normal gray matter | |||
|---|---|---|---|---|---|
| CBFmax | CBFmin | CBFmean | CBFmean | CBFmean | |
| Absolute values | 89.25 ± 39.50 | 42.33 ± 11.79 | 66.98 ± 18.03 | 35.19 ± 7.75 | 33.92 ± 8.48 |
| Relative values | 2.61 ± 0.64 | 1.34 ± 0.53 | 2.03 ± 0.53 | 1.08 ± 0.32 | – |
CBFmax/CBFmin/CBFmean represent the maximum, minimum, and average value of cerebral blood flow (CBF), respectively. Relative values are the CBF values of high-perfusion and edema area normalized by that of normal gray matter.
CBF values before and during radiotherapy (ml/100 g/min).
| High-perfusion area | Edema area | Normal gray matter | |||
|---|---|---|---|---|---|
| CBFmax | CBFmin | CBFmean | CBFmean | CBFmean | |
| Before radiotherapy | 77.17 ± 17.45 | 45.83 ± 9.47 | 66.09 ± 13.45 | 38.05 ± 7.81 | 40.44 ± 12.28 |
| During radiotherapy | 86.00 ± 35.79 | 50.67 ± 11.64 | 69.31 ± 16.96 | 40.23 ± 12.57 | 38.14 ± 12.60 |
| Test statistic | -0.647 | -1.336* | -0.314 | -0.492 | 1.077 |
|
| 0.546 | 0.239 | 0.753 | 0.644 | 0.331 |
CBFmax/CBFmin/CBFmean represent the maximum, minimum, and average values of cerebral blood flow (CBF), respectively. The asterisk (*) represents the test statistic of Wilcoxon test and the others are t-test values.
Figure 2Tuning parameter (λ) selection in the LASSO regression.
Figure 3The coefficients of screened features using the LASSO regression.
Figure 4Receiver operating characteristic (ROC) curves.
Figure 5A 74-year-old patient with non-enhancing low-grade glioma (WHO grade II astrocytoma) showed focal contrast enhancement within a prior non-enhanced and high-perfusion area at 20 sessions of radiotherapy (40 Gy). (A) Planning plain-CT image. (B) Contrast-enhanced T1-weighted imaging (CE-T1WI) before radiotherapy. (C) T2 fluid-attenuated inversion recovery (T2 Flair) image before radiotherapy. (D) Three-dimensional arterial spin labeling (3D-ASL) image before radiotherapy. (E) CE-T1WI at 20 sessions of radiotherapy. (F) Fusion image of (D, E).
Figure 6A 62-year-old patient with non-enhancing low-grade glioma (WHO grade II astrocytoma) showed focal post-radiotherapy contrast enhancement within a prior non-enhanced and high-perfusion area at 3 months following radiotherapy. The patient had clinical symptoms such as weakness of the right lower limb, considering the tumor progression. (A) Planning contrast-enhanced CT (CE-CT) image. (B) Contrast-enhanced T1-weighted imaging (CE-T1WI) before radiotherapy. (C) T2 fluid-attenuated inversion recovery (T2 Flair) image before radiotherapy. (D) three-dimensional arterial spin labeling (3D-ASL) image before radiotherapy. (E) CE-T1WI at 3 months following radiotherapy. (F) Fusion image of (D, E).